Fig. 1.

. Effect of anti-CTLA-4 and anti-PD-1 immunotherapies in subcutaneous based syngeneic CT26 colorectal cancer model. A. Impact of anti-CTLA-4 and -PD-1 immunotherapies in monotherapy or in combination on CT26 tumor growth. B-E Individual growth curve for each mouse treated with control (B), anti-CTLA-4 (C); anti-PD-1 (D), or combination (E). Anti-CTLA-4 and anti-PD-1 were administered at days 6, 9, and 12 post-tumor cell inoculation at respective doses of 100 and 200 µg i.p. per animal. Statistical differences between the groups were determined using by mixed-effects model (REML) with repeated measures followed by Tukey multiple comparisons test (control vs. other groups: * p  ≤  0.05, ** p ≤  0.01, *** p ≤ 0.001, **** p < 0.0001; anti-PD-1 vs. Anti-CTLA-4 # p ≤ 0.001; anti-PD-1 vs. combination & p ≤ 0.0001). Pooled data represent mean ± SD. n = 9–10 mice per group.